List view / Grid view
Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.
Researchers in Norway have identified a promising oral drug combination that may stop the replication of enteroviruses, a group of viruses responsible for illnesses ranging from the common cold to type 1 diabetes.
Discover how Chromatin Bioscience’s synthetic promoters are transforming gene therapy by enhancing precision, boosting safety and improving manufacturing efficiency.
Scientists have developed lab-grown liver organoids with functional zonation, a discovery that brings regenerative medicine a step closer to personalised, transplant-free liver therapy.
Judy Ashworth, CMO of Novadip Biosciences, shares her journey in advancing treatments for rare paediatric conditions and championing diversity in STEM.
Researchers have developed a test that accurately predicts whether patients with ALK-positive lung cancer will respond to targeted treatments. This could significantly enhance personalised cancer therapies and overcome treatment resistance.
Men and women heal bone injuries through distinct biological processes, challenging assumptions in regenerative medicine. The findings support the development of personalised implants and more effective, sex-specific treatment strategies.
Researchers at ETH Zurich in Switzerland have mapped the complex network cells use to repair their genetic material, revealing previously hidden vulnerabilities in cancer cells.
Tubulis, led by CEO Dominik Schumacher, is advancing cancer treatment through next-generation antibody-drug conjugates (ADCs) designed to target solid tumours more effectively. Find out how the company is rapidly progressing its ADC pipeline to offer more precise and lasting treatment options for patients.
New research reveals that the flexible ‘fuzzy coat’ surrounding α-synuclein fibrils plays a critical role in how Parkinson’s disease spreads between brain cells.
A specialised group of immune cells in the gut has been found to prevent allergic reactions - a discovery that could lead to new treatments for allergies and autoimmune diseases.
Find out how LB Pharmaceuticals' LB-102 is advancing schizophrenia treatment. This first-in-class antipsychotic demonstrates strong efficacy, safety and tolerability, potentially addressing both acute and negative symptoms. Explore its potential impact on neuropsychiatric drug discovery.
Discover how Immorta Bio's cellular therapies are addressing cancer and liver failure, with the potential to transform healthcare.
A preclinical study conducted by researchers at Weill Cornell Medicine have demonstrated a new gene-editing strategy to treat short bowel syndrome (SBS), a life-threatening condition in which patients lack a functional small intestine.
A team of scientists from the University of Birmingham has discovered a powerful new treatment for psoriasis. The treatment uses a tripeptide that has shown steroid-level effectiveness in reducing symptoms, offering fresh hope for the long-term management of this chronic skin condition.
